New weapon against tough ovarian cancer enters human testing

NCT ID NCT06234423

Recruiting now Disease control Sponsor: OnCusp Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called CUSP06 for people with ovarian cancer that has stopped responding to platinum chemotherapy, as well as other advanced solid tumors. CUSP06 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to cells that carry a specific marker (CDH6). The study will enroll about 263 participants to first find the safest dose and then check for early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CUSP06 (an antibody-drug conjugate that targets CDH6 on cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for people with ovarian cancer that no longer responds to platinum chemotherapy.
What could go wrong: This is a very early Phase 1 trial, so the main goals are safety and dosing—not yet proof of effectiveness. It may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER SOLID TUMOR

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Mater Cancer Care Centre
RECRUITING

South Brisbane, Queensland, 4101, Australia
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
Mount Sinai Medical Center
RECRUITING

Miami Beach, Florida, 33140, United States
NEXT Oncology
RECRUITING

Houston, Texas, 77054, United States
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
NYU Cancer Institute Clinical Cancer Center
RECRUITING

New York, New York, 10016, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
Stephenson Cancer Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Yale University
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.